Referências bibliográficas: Edição 4

Pág. 13 – Frontiers

Lições sobre inovação ultrarrápida da pandemia de covid-19Por Georg Von Krogh, Burcu Kucukkeles e Shiko M. Ben-Menahem

1. M.J. Barratt and D.E. Frail, eds., “Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs” (Hoboken, New Jersey: John Wiley & Sons, 2012).2. K. Kupferschmidt and J. Cohen, “Race to Find COVID-19 Treatments Accelerates,” Science 367, no. 6485 (March 27, 2020): 1412-1413.3. “Novartis Announces Plan to Initiate Clinical Study of Jakavi in Severe COVID-19 Patients and Establish International CompassionateUser Program,” Novartis, April 2, 2020, www.novartis.com.4. M. Sheetz, “Jeff Bezos’ Blue Origin is 3D Printing Parts for Face Shields to Help Fightthe Coronavirus Crisis,” CNBC, April 7, 2020, www.cnbc.com.5. E. von Hippel and G. von Krogh, “Identifying Viable ‘Need-Solution Pairs’: Problem Solving Without Problem Formulation,” Organization Science 27, no. 1 (January-February 2016):207-221.6. “AI and Control of COVID-19 Coronavirus,” Council of Europe, accessed April 21, 2020, www.coe.int.7. “MGA Announces: Initiative ‘3D Printing Fights Corona,’” Mobility Goes Additive,April 6, 2020, https://mobilitygoesadditive.org.8. B. Kucukkeles, S.M. Ben-Menahem, andG. von Krogh. “Small Numbers, Big Concerns: Practices and Organizational Arrangements in Rare Disease Drug Repurposing,” Academy of Management Discoveries 5, no. 4 (December 2019): 415-437.9. S. Turney, “VU Engineers and VUMC Doctors Team Up for Open-Source Ventilator Design,” Vanderbilt University, March 27, 2020, https://news.vanderbilt.edu.